About Us

StemInov is a clinical stage company, spin-off from Nancy’s Teaching Hospital and Lorraine Region’s Uni.

The company develops an off-the-shelf, allogenic stem cell therapy treatment, in the field of inflammatory pathologies, with a focus on critical care.

The company's lead product candidate “WhartSep” is based on Stem cells from Wharton jelly of the umbilical cord (WJ-MSC) and classified by the EMA (European Medicines Agency) as an ATMP (Advanced-Therapy Medicinal Product).

WhartSep is a new concept in immunomodulation and adaptive medicine thanks to its immunomodulation properties.

Our first indication is the patented treatment of severe pneumonia in entry of phase Ib